_____________________________________________________________________________________________________ *Corresponding author: E-mail: dryouns@hotmail.com; Cardiology and Angiology: An International Journal 3(4): 175-180, 2015, Article no.CA.2015.017 ISSN: 2347-520X SCIENCEDOMAIN international www.sciencedomain.org Enoxaparin for Early Anticoagulation after Mitral Valve Repair Younes Moutakiallah 1* , Roland Henaine 2 , Mehdi Bamous 1 , Jacques Robin 2 , Jean Ninet 2 and Jean-François Obadia 2 1 Faculty of Medicine and Pharmacy of Rabat, Department of Cardiac surgery, Mohammed V University, Mohammed V Military Hospital, Rabat, Morocco. 2 Faculty of Medicine Lyon Est, University of Claude Bernard Lyon 1, Hospices Civils de Lyon, Groupement Hospitalier Est, Hôpital Cardiologique Louis Pradel, Cardiac Surgery Unit, Lyon, France. Authors’ contributions This work was carried out in collaboration between all authors. Authors YM, RH and J-FO designed the study, wrote the protocol and wrote the first draft of the manuscript. Authors MB and YM managed the literature searches. Authors YM, JR and JN collected, analyzed and interpreted data. All authors read and approved the final manuscript. Article Information DOI: 10.9734/CA/2015/17779 Editor(s): (1) Francesco Pelliccia, Department of Heart and Great Vessels, University La Sapienza, Rome, Italy. Reviewers: (1) Alexander Berezin, Internal Medicine Department, Zaporozhye Medical University, Ukraine. (2) Yoshio Misawa, Cardiovascular Surgery, Jichi Medical University, Japan. (3) Anonymous, Spain. (4) John Skoularigis, Larissa University Hospital, Cardiology Department, Larissa-Greece. Complete Peer review History: http://www.sciencedomain.org/review-history.php?iid=843&id=26&aid=9004 Received 25 th March 2015 Accepted 14 th April 2015 Published 27 th April 2015 ABSTRACT Introduction: Despite recent progress and technological advances, heart valve surgery remains associated with a high rate of thromboembolic complications requiring anticoagulation, which must be both safe and effective to prevent any thromboembolic or bleeding events. Objectives: The objective of this study was to verify the efficacy and the safety of Low Molecular Weight Heparin followed by vitamin K antagonists for the early anticoagulation after mitral valve repair. Patients and Methods: This work was conducted as a prospective study. We selected 120 consecutive patients who underwent mitral valve repair and received enoxaparin as bridge between continuous unfractionated heparin and fully effective vitamin K antagonist therapy. The mean age was 63.6±13.5 years (15-84 years). Original Research Article